Distinct Cellular Mechanisms Underlie Anti-CTLA-4 and Anti-PD-1 Checkpoint Blockade. - Wikidata - wikimedia - TriplyDB

Distinct Cellular Mechanisms Underlie Anti-CTLA-4 and Anti-PD-1 Checkpoint Blockade.

Distinct Cellular Mechanisms Underlie Anti-CTLA-4 and Anti-PD-1 Checkpoint Blockade.

http://www.wikidata.org/entity/Q47958949

about

Gene Regulatory Network Rewiring in the Immune Cells Associated with Cancer.Immune Checkpoint Molecules on Tumor-Infiltrating Lymphocytes and Their Association with Tertiary Lymphoid Structures in Human Breast Cancer.PD-1/PD-L1 Blockade: Have We Found the Key to Unleash the Antitumor Immune Response?Synergies of Targeting Tumor Angiogenesis and Immune Checkpoints in Non-Small Cell Lung Cancer and Renal Cell Cancer: From Basic Concepts to Clinical Reality.Melanoma: Genetic Abnormalities, Tumor Progression, Clonal Evolution and Tumor Initiating Cells.Checkpoint Blockade Toxicity and Immune Homeostasis in the Gastrointestinal Tract.Generating Quantitative Cell Identity Labels with Marker Enrichment Modeling (MEM).Immune-suppressive effects of interleukin-6 on T-cell-mediated anti-tumor immunity.Mechanisms of resistance to immune checkpoint inhibitors.Re-Emergence of Dendritic Cell Vaccines for Cancer Treatment.Cancer immunotherapy: The dark side of PD-1 receptor inhibition.LXR/ApoE Activation Restricts Innate Immune Suppression in Cancer.Predictive immune biomarkers: an unattainable chimera?A role for T helper cells in anti-CTLA-4 therapy.Checks and Balances in Autoimmune Vasculitis.The Complex Interplay between Chronic Inflammation, the Microbiome, and Cancer: Understanding Disease Progression and What We Can Do to Prevent It.Genomic Features of Response to Combination Immunotherapy in Patients with Advanced Non-Small-Cell Lung Cancer.Comprehensive immunoproteogenomic analyses of malignant pleural mesothelioma.Baseline antibody profiles predict toxicity in melanoma patients treated with immune checkpoint inhibitors.Anti-CTLA-4 therapy requires an Fc domain for efficacy.Genotypic and phenotypic signatures to predict immune checkpoint blockade therapy response in patients with colorectal cancer.Importance of immune monitoring approaches and the use of immune checkpoints for the treatment of diffuse intrinsic pontine glioma: From bench to clinic and vice versa (Review).Immune consequences of anti-angiogenic therapyin renal cell carcinoma.T Cell Calcium Signaling Regulation by the Co-Receptor CD5.Long non-coding RNA Lnc-Tim3 exacerbates CD8 T cell exhaustion via binding to Tim-3 and inducing nuclear translocation of Bat3 in HCC.Immunotherapy in renal cell carcinoma: latest evidence and clinical implications.Immune Monitoring of Cancer Patients Prior to and During CTLA-4 or PD-1/PD-L1 Inhibitor Treatment.Gut microbiome modulates efficacy of immune checkpoint inhibitors.Phase Ib/II trial evaluating the safety, tolerability and immunological activity of durvalumab (MEDI4736) (anti-PD-L1) plus tremelimumab (anti-CTLA-4) combined with FOLFOX in patients with metastatic colorectal cancer.Combining Immunotherapy and Radiotherapy for Cancer Treatment: Current Challenges and Future Directions.Efficacy and immune activation of ipilimumab in early-stage lung cancer patients.Lack of Sprouty 1 and 2 enhances survival of effector CD8 T cells and yields more protective memory cells Not All Immune Checkpoints Are Created Equal Combination of dual mTORC1/2 inhibition and immune-checkpoint blockade potentiates anti-tumour immunity Present and future of cancer immunotherapy: A tumor microenvironmental perspective Immunological-based approaches for cancer therapy Oncolytic virus and PD-1/PD-L1 blockade combination therapy Biomarkers for Immune Checkpoint Inhibitors in Melanoma Prognostic Factors for Checkpoint Inhibitor Based Immunotherapy: An Update With New Evidences Checkpoint Blockade Reverses Anergy in IL-13Rα2 Humanized scFv-Based CAR T Cells to Treat Murine and Canine Gliomas

P2860

Q47095688-4E3D0CAB-FFEC-48CD-9754-8BE9AFF39E40 Q47109363-2C55F41D-D31F-4BDA-BC2D-CFD54AE62CC7 Q47120629-9809F37D-54EA-4697-9FDB-8B6F8B9592F7 Q47135054-3CD9E767-8FAB-42FC-9D6F-2A06CC72571A Q47227422-E5D96F36-BF13-48BA-9BEC-D1AC1FDD555F Q47304240-D812ED29-5626-4981-A5E0-5F7042E12DC9 Q47561358-EE2DBA62-071A-4EDD-92DA-D37746A148F4 Q48090319-B7A414B8-E924-4D6B-956E-4A7F342890DF Q49537326-194C1626-BA83-4A8D-8E00-6C56D3F5BB5D Q49835172-5893DA1A-3C4B-48B2-9119-6B845B8AEE4E Q49971148-31A150F2-CF64-48A4-BD10-FD72818874DE Q50034376-21FEEEC1-40B4-4F78-8859-23EE08B0DB86 Q50199694-67B18CDE-A0A0-4F1F-B650-548484C1FC70 Q50231751-2AB6C325-E0C2-4797-B837-AA206FD80C9B Q51764698-73EF1374-38FA-4C69-9D5F-4F71ADECF590 Q52349005-617F10B4-CC1D-4CCF-88F2-A008215FF085 Q52587406-2DE3383C-5C43-4100-A465-0C56A7BE1EEF Q52606456-55B7011A-E621-4AD0-96F9-9CEA12AB878A Q52615452-DC85CCB2-E0AF-43F6-BCA0-00127AA0CAAA Q52629626-A5B932CC-0CDB-409D-A972-42777E03FEB9 Q52666692-1A2A6CC1-B90D-488A-BD66-FBD10B02C42E Q52683991-1A102976-A426-4F9E-84D6-0E376432A405 Q54981236-F54DC820-3827-42ED-9100-52698114AFCF Q55000833-9596E236-D3FB-4088-9E45-6198597D0EBB Q55007862-0B61760B-86D7-451D-B765-85679440F592 Q55101776-30EFCAC3-E67B-424A-8C84-1EE851069FEA Q55114350-14D40264-27ED-4941-B215-FD461A0F4AC5 Q55240704-B3F2E479-BBB7-49BF-966C-B31180EAC944 Q55264112-7AF1E8B5-FB15-4585-8074-C8BB3FAAAE51 Q55287125-10C68305-113E-43F8-BADD-C2B9A9721010 Q55709749-5BDA609E-8970-4829-9957-75B18968CABB Q56886922-3A6211AB-E4F7-48CF-8246-9B17AED3A1C4 Q56889626-361AE2A8-DA9E-44D4-B81B-7F0C7BA86880 Q56892381-892D99B5-BE7B-430A-9F79-8A85B1388B64 Q57144510-5E6E6B8B-01B7-4B78-B737-6DD10738DFC4 Q57168423-8B295FF0-3C39-4DBE-AC86-6866A581FAD0 Q57174025-E77694BD-F77D-4427-BC63-8005E26E7920 Q57175477-325A646B-51C7-403F-8DE1-13CAB3E8811C Q57191808-BE0C6189-4592-4C68-8201-C5FF39E33A02 Q57300937-784FAC76-0610-4688-9D47-DB58A53D8ABB

P2860

Distinct Cellular Mechanisms Underlie Anti-CTLA-4 and Anti-PD-1 Checkpoint Blockade.

http://www.wikidata.org/entity/Q47958949

description

2017 nî lūn-bûn

@nan

2017年の論文

@ja

2017年学术文章

@wuu

2017年学术文章

@zh

2017年学术文章

@zh-cn

2017年学术文章

@zh-hans

2017年学术文章

@zh-my

2017年学术文章

@zh-sg

2017年學術文章

@yue

2017年學術文章

@zh-hant

name

Distinct Cellular Mechanisms Underlie Anti-CTLA-4 and Anti-PD-1 Checkpoint Blockade.

@en

Distinct Cellular Mechanisms Underlie Anti-CTLA-4 and Anti-PD-1 Checkpoint Blockade.

@nl

type

label

Distinct Cellular Mechanisms Underlie Anti-CTLA-4 and Anti-PD-1 Checkpoint Blockade.

@en

Distinct Cellular Mechanisms Underlie Anti-CTLA-4 and Anti-PD-1 Checkpoint Blockade.

@nl

altLabel

Distinct Cellular Mechanisms Underlie Anti-CTLA-4 and Anti-PD-1 Checkpoint Blockade

@en

prefLabel

Distinct Cellular Mechanisms Underlie Anti-CTLA-4 and Anti-PD-1 Checkpoint Blockade.

@en

Distinct Cellular Mechanisms Underlie Anti-CTLA-4 and Anti-PD-1 Checkpoint Blockade.

@nl

P1433

Q47958949-4D5537E3-C99C-4088-87D7-B9AECFB9B652

P1476

Q47958949-6D53ABBB-30DD-42B3-B4E3-6CBA7919FADF

P2093

Q47958949-1444FAA5-9E37-40F8-B2F0-A383EA7C2C2D

Q47958949-2B22BCD3-A390-486C-ABBB-C2D7BBA4BBD4

Q47958949-7095950B-3DD4-4B43-B554-55496B9154E5

Q47958949-7A59F7E6-60B4-433E-B57C-8D5A0DC5E2ED

Q47958949-7CD84B9E-2A2D-422B-ACE9-0B71509272EC

Q47958949-BBC6CB30-A001-4A53-B2C6-2E1680951055

P2860

Q47958949-013344B7-84E2-4BEE-B413-5234F1B680BF

Q47958949-021E6C6A-DFAE-48D4-88E0-C52F9A408544

Q47958949-0E8FC25D-16CC-49F9-9FDD-9D256C834168

Q47958949-116A6BDE-4A6A-46D6-A25E-DEB6806D4F6E

Q47958949-1C059B7B-B136-445E-B450-EB529C39981E

Q47958949-1D605E5F-D8D8-4367-AF02-AC6B1EAA730B

Q47958949-2049AC95-9985-47E9-BA79-5F93CB7B1237

Q47958949-2193EBD7-CA3D-4932-9F9C-2E44941A2354

Q47958949-21B2970D-4508-49A1-BCE4-EFF1DBFD69E6

Q47958949-23C04EB5-9843-4765-A53F-E210D522C9B1

P304

Q47958949-03EA2029-6D66-41A3-8B9F-424A490D5868

P31

Q47958949-F929C5D1-4EC5-4F6D-9B02-7DE72FC501D9

P356

Q47958949-408C172E-82F9-4EB9-959F-80F61850BE6C

P407

Q47958949-BC30333E-AB23-41B1-8FAD-1FB5229EFB12

P433

Q47958949-0DA1B26A-2032-4051-A4D3-6162231229EA

P478

Q47958949-09D0FDC9-1DD9-44EF-968D-DB43646E8246

P50

Q47958949-2A030A34-6938-46C0-B76B-27CB19D90E10

Q47958949-53D02FA3-796E-4A1F-8236-C78F4BB12EF3

Q47958949-676E81C3-6CC5-41E0-AA6E-669472AAE4BC

Q47958949-8EAF56E4-BF64-4797-B45C-61C1F7C3E343

Q47958949-E5F93D64-3C75-4495-B282-48E386BF3484

P577

Q47958949-F825EEED-CFE3-4E80-92FA-7D73AAFE01BB

P698

Q47958949-5AED20F8-654E-40A6-9E16-59241287F581

P932

Q47958949-F4EEFDA8-4918-48D8-A252-34FCB0F68953

P356

J.CELL.2017.07.024

P1433

P1476

Distinct Cellular Mechanisms Underlie Anti-CTLA-4 and Anti-PD-1 Checkpoint Blockade.

@en

P2093

Dana Pe'er

http://www.w3.org/2001/XMLSchema#string

Jacob H Levine

http://www.w3.org/2001/XMLSchema#string

Jennifer A Wargo

http://www.w3.org/2001/XMLSchema#string

Jing Wang

http://www.w3.org/2001/XMLSchema#string

Padmanee Sharma

http://www.w3.org/2001/XMLSchema#string

Yang Zhao

http://www.w3.org/2001/XMLSchema#string

P2860

Single-cell mass cytometry of differential immune and drug responses across a human hematopoietic continuum

VarScan 2: somatic mutation and copy number alteration discovery in cancer by exome sequencing

Fc-dependent depletion of tumor-infiltrating regulatory T cells co-defines the efficacy of anti-CTLA-4 therapy against melanoma

Safety, activity, and immune correlates of anti-PD-1 antibody in cancer

Fast and accurate short read alignment with Burrows-Wheeler transform

Engagement of the PD-1 immunoinhibitory receptor by a novel B7 family member leads to negative regulation of lymphocyte activation

CD28 and CTLA-4 have opposing effects on the response of T cells to stimulation

Nivolumab plus ipilimumab in advanced melanoma.

The blockade of immune checkpoints in cancer immunotherapy

Safety and Activity of Anti–PD-L1 Antibody in Patients with Advanced Cancer

P304

1120-1133.e17

http://www.w3.org/2001/XMLSchema#string

P31

scholarly article

P356

10.1016/J.CELL.2017.07.024

http://www.w3.org/2001/XMLSchema#string

P407

P433

6

http://www.w3.org/2001/XMLSchema#string

P478

170

http://www.w3.org/2001/XMLSchema#string

P50

Miles C Andrews

Alexandria P Cogdill

James P. Allison

Nana-Ama A S Anang

P577

2017-08-09T00:00:00Z

http://www.w3.org/2001/XMLSchema#dateTime

P698

28803728

http://www.w3.org/2001/XMLSchema#string

P932

5591072

http://www.w3.org/2001/XMLSchema#string